Johnson & Johnson
EU lobbying footprint — who they meet, and on what. Built only from official disclosures, every meeting cited.
Johnson & Johnson has 87 disclosed EU lobbying meetings from 2020-06-26 to 2026-10-14: 35 with the European Commission and 52 with Members of the European Parliament. Source: EU Transparency Register no. 75617941310-89, Commission disclosures and MEP declarations.
Lobbying profile
as declared 2026-02-25- Category
- Companies & groups
- Legal status
- Corporation
- Declared lobbying cost
- €900,000
- Lobbying FTEs
- 6.25
- Members
- 4
Files it’s lobbying on
The org's disclosed policy areas, ranked by number of meetings.
Declared fields of interest
Business and industry · Climate action · Competition · Customs · Digital economy and society · Economy, finance and the euro · Employment and social affairs · Environment · Humanitarian aid and civil protection · Institutional affairs · International co-operation and development · Public health
At a glance
The officials and MEPs most often met, by disclosed-meeting count.
- Chiara Galiffa3
- Olivér Várhelyi2
- Werner Stengg2
- Geneviève Tuts2
- Manuel Mateo Goyet1
- KULJA András Tivadar3
- KELLEHER Billy3
- CASTILLO Laurent3
- SOKOL Tomislav3
- ANDRIUKAITIS Vytenis Povilas3
Disclosed meetings
Newest first, showing the most recent 60 of 87. EC = European Commission, EP = Member of the European Parliament.
- 2026-10-14ECManuel Mateo Goyet · Head of UnitCloud and Ai Development Actsource ↗
- Battery labelingsource ↗
- Biotechsource ↗
- 2026-07-08ECHeinz Jansen · Principal AdviserCompetitiveness Coordination Tool – exchanges with the industrysource ↗
- 2026-07-03ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiLife Sciences Roundtablesource ↗
- 2026-07-01ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiMedical devices reformsource ↗
- Biotech Actsource ↗
- Biotech Act Isource ↗
- EU Biotech Actsource ↗
- 2026-06-05ECIoan-Dragos Tudorache · Cabinet of Executive Vice-President Stéphane SéjournéEU competitiveness agendasource ↗
- 2026-06-04ECSilvia Bartolini · Cabinet of Executive Vice-President Henna VirkkunenTech Sovereignty Package- CADAsource ↗
- 2026-06-03ECArthur Corbin · Cabinet of Executive Vice-President Stéphane SéjournéIndustrysource ↗
- Biotech Actsource ↗
- Introduction, exchange of views on Biotech Actsource ↗
- EU Biotech Actsource ↗
- Biotech Actsource ↗
- Biotech Actsource ↗
- SANT COMMITTEE ONGOING WORKsource ↗
- 2026-05-07ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičLatest developments in EU-US relationssource ↗
- FP10source ↗
- Pharmaceutical Issuessource ↗
- 2026-04-15EPCASTILLO LaurentDispositifs médicauxsource ↗
- MDR Revisionsource ↗
- Health Policysource ↗
- Biotech Actsource ↗
- Biotech Actsource ↗
- Biotech Act Isource ↗
- 2026-02-03ECMirzha De Manuel · Cabinet of Commissioner Valdis DombrovskisImplementation of the EU pay transparency directivesource ↗
- Trade relations and business challengessource ↗
- 2026-01-16ECIoana Diaconescu · Head of UnitJohnson & Johnson requested this meeting to engage with DG TAXUD regarding the simplification agenda in the field of direct taxation.source ↗
- Health policysource ↗
- FDI and critical medicines provisionsource ↗
- 2025-12-08EPCASTILLO LaurentPharmasource ↗
- 2025-12-03ECUlla Schwager · Head of UnitExchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sectorsource ↗
- 2025-12-01ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiDigital and AI as an enabler in healthcaresource ↗
- 2025-12-01ECPatricia Reilly · Cabinet of President Ursula von der LeyenCompetitiveness and sustainable healthcaresource ↗
- 2025-12-01ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiDigital and AI as an enabler in healthcaresource ↗
- 2025-10-28ECMaroš Šefčovič · Cabinet of Commissioner Maroš ŠefčovičPriorities of the EU’s trade agendasource ↗
- 2025-10-28ECAdam Romanowski · Cabinet of Commissioner Maroš ŠefčovičPriorities of the EU’s trade agendasource ↗
- 2025-10-17ECBernd Biervert · Cabinet of Commissioner Maroš ŠefčovičEU – US relationssource ↗
- 2025-10-17ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičEU – US relationssource ↗
- 2025-09-25ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičEU – US relationssource ↗
- Critical Medicines Act and other prioritiessource ↗
- Presentation of Position on the Critical Medicines Actsource ↗
- Critical Medicines Act / address the root causes of medicine shortages while strengthening Europe’s life sciences ecosystem and competitivenesssource ↗
- Critical Medicines Actsource ↗
- Industrial Policysource ↗
- tematiche sanitariesource ↗
- Critical Medicines Actsource ↗
- Critical Medicines Actsource ↗
- Ongoing Legislationsource ↗
- CMAsource ↗
- Health policysource ↗
- Critical Medicinessource ↗
- Critical medicines actsource ↗
- Meeting regarding Critical Medicines Actsource ↗
- Health Policysource ↗
- Critical Medicines Actsource ↗
- Critical Medicines Actsource ↗
- 2025-06-03ECKilian Gross · Head of UnitExchange of views on application of the AI Act to the healthcare sector.source ↗
Frequently asked
How many EU lobbying meetings has Johnson & Johnson disclosed?
Johnson & Johnson (EU Transparency Register no. 75617941310-89) appears in 87 disclosed meetings with EU officials and MEPs between 2020-06-26 and 2026-10-14: 35 with the European Commission and 52 with Members of the European Parliament.
What does Johnson & Johnson lobby on?
Johnson & Johnson's disclosed EU meetings most often concern Technology, Health, Industry, Trade. Every meeting and its topic is listed with its official source on this page.
Who does Johnson & Johnson meet in Brussels?
Across its disclosed meetings, Johnson & Johnson has met Commission officials including Chiara Galiffa, Olivér Várhelyi, Werner Stengg, and MEPs including KULJA András Tivadar, KELLEHER Billy, CASTILLO Laurent. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Related on the graph
The same footprint, mapped onto the topics and files it touches.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.
See your company’s overlap with Johnson & Johnson — and the rest of the corpus.
Enter your company and Lex builds a cited Exposure Map in about 30 seconds. Free, no login.